Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase II study of IMP4297 in BRCA1/2-mutated advanced ovarian, fallopian tube, or primary peritoneal cancer
CTR20190652Phase 2Active
- Sponsor
- IMPACT Therapeutics
- Start
- Oct 2019
- Modality
- Small Molecules
- Countries
- 1
01
Overview
A Phase 2 trial of senaparib in ovarian cancer, fallopian tube cancer (PFTC), primary peritoneal cancer (PPC), sponsored by IMPACT Therapeutics. Started Oct 2019; status: active.
02
Drugs
senaparib
03
Conditions
ovarian cancerfallopian tube cancer (PFTC)primary peritoneal cancer (PPC)
Beyond the preview
Go deeper on CTR20190652.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on CTR20190652.